csrxp_admin, Author at CSRxP - Page 5 of 80

THEY SAID IT!: LAWMAKERS ROAST BIG PHARMA’S PATENT ABUSE, CALL FOR ACTION ON BIPARTISAN SOLUTIONS TO HOLD THE PHARMACEUTICAL INDUSTRY ACCOUNTABLE

Senate Judiciary Committee Puts Spotlight on Big Pharma’s Anti-Competitive… Read More

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold… Read More

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on… Read More

DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING

Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and… Read More

BIG PHARMA EARNINGS WATCH: ELI LILLY, NOVO NORDISK, ABBVIE, AMGEN, GLAXOSMITHKLINE AND PFIZER

Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost… Read More

DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics… Read More

CSRXP APPLAUDS EXPANDED FTC CRACK DOWN ON BIG PHARMA’S SHAM PATENTS IN THE ORANGE BOOK

Commission Builds on Previous Action by Targeting More Than 300 Patents,… Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS, MERCK, ASTRAZENECA, BRISTOL MYERS SQUIBB AND SANOFI

Big Pharma Continues Raking in Big Profits and Expectation-Beating Revenue… Read More

DOSE OF REALITY: NEW ANALYSES UNDERSCORE HOW BIG PHARMA’S EGREGIOUS PRICING OF WEIGHT LOSS DRUGS IS UNSUSTAINABLE

Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of… Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Big Pharma Giant Kicks Off Q1 Earnings After Hiking Prices More Than 40 Times… Read More

SECOND OPINION: BIG PHARMA’S OUT-OF-POCKET PLANS ON BRAND NAME INHALERS MAY BE DESIGNED TO FURTHER UNDERMINE COMPETITION

Big Pharma’s Announcements Designed to Deflect from Criticism and Scrutiny… Read More

CSRXP COMMENDS PRESIDENT BIDEN FOR HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE AND EGREGIOUS PRICING ON BRAND NAME INHALERS

President Says ‘Drug Companies Are Charging Exorbitant Prices’ in Press… Read More